[
  {
    "ts": null,
    "headline": "Gilead Sciences to Present at Upcoming Investor Conference",
    "summary": "FOSTER CITY, Calif., December 20, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:",
    "url": "https://finnhub.io/api/news?id=5c30fc451a9e9caf73cdc685c079002d0233d4af3aa9a8c28f22f25f10597927",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734728700,
      "headline": "Gilead Sciences to Present at Upcoming Investor Conference",
      "id": 132084308,
      "image": "https://s.yimg.com/ny/api/res/1.2/1xvpAnuZJs3BSZ8Ir3NMOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/c540a71abfe7c2bbf6918ac2a7a02bca",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., December 20, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:",
      "url": "https://finnhub.io/api/news?id=5c30fc451a9e9caf73cdc685c079002d0233d4af3aa9a8c28f22f25f10597927"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?",
    "summary": "GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.",
    "url": "https://finnhub.io/api/news?id=729fec09858569812296bc8ab7e6eebd399e17bd2011179d62db1865a57c1114",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734717600,
      "headline": "Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?",
      "id": 132084309,
      "image": "https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.",
      "url": "https://finnhub.io/api/news?id=729fec09858569812296bc8ab7e6eebd399e17bd2011179d62db1865a57c1114"
    }
  },
  {
    "ts": null,
    "headline": "Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?",
    "summary": "Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=5e1dfe395dcfda5c21789f90290dd9e209f431651a50e2551524eccba10b4f7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734705609,
      "headline": "Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?",
      "id": 132076371,
      "image": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=5e1dfe395dcfda5c21789f90290dd9e209f431651a50e2551524eccba10b4f7d"
    }
  },
  {
    "ts": null,
    "headline": "Impax US Sustainable Economy Fund Q3 2024 Commentary",
    "summary": "The Impax US International Sustainable Economy Fund outperformed its benchmark in the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=8a28b802c2856e0307a1310c4722d6042f42bed7622ae34e33bbab0f11ea0e0b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734678300,
      "headline": "Impax US Sustainable Economy Fund Q3 2024 Commentary",
      "id": 132071401,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1580372641/image_1580372641.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The Impax US International Sustainable Economy Fund outperformed its benchmark in the third quarter of 2024. Click here to read the full commentary. \n",
      "url": "https://finnhub.io/api/news?id=8a28b802c2856e0307a1310c4722d6042f42bed7622ae34e33bbab0f11ea0e0b"
    }
  }
]